Brown, Lisle/Cummings’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Brown, Lisle/Cummings's BMY Position: Q2 2026 in Review
Brown, Lisle/Cummings increased its Bristol-Myers Squibb (BMY) stake by 11% in Q2 2026, buying an estimated $143K and bringing the position to 25,387 shares worth $1.46M. The position accounts for 0.33% of the portfolio, ranked #73.
Brown, Lisle/Cummings first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.89M in Q1 2022. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Brown, Lisle/Cummings held 25,387 shares of Bristol-Myers Squibb worth $1.46M as of Q2 2026.
- Brown, Lisle/Cummings bought 2,496 Bristol-Myers Squibb shares in Q2 2026, an estimated $143K.
- Bristol-Myers Squibb made up 0.33% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #73 holding.
- Brown, Lisle/Cummings first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
- Brown, Lisle/Cummings's Bristol-Myers Squibb position peaked at $1.89M in Q1 2022.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.